TNFi is associated with positive outcome, but JAKi and rituximab are associated with negative outcome of SARS-CoV-2 infection in patients with RMD.
Anne Constanze RegiererRebecca HasseliMartin SchaeferBimba Franziska HoyerAndreas KrauseHanns-Martin LorenzAlexander PfeilJutta RichterTim SchmeiserHendrik Schulze-KoopsAnja StrangfeldReinhard E VollChristof SpeckerUlf Mueller-LadnerPublished in: RMD open (2021)
General risk factors for severity of COVID-19 play a similar role in patients with RMDs as in the normal population. Influence of disease activity on COVID-19 outcome is of great importance as patients with high disease activity-even without glucocorticoids-have a worse outcome. Patients on TNFi show a better outcome of SARS-CoV-2 infection than patients on MTX. Immunosuppressants, rituximab and JAKi are associated with more severe course.
Keyphrases